121 related articles for article (PubMed ID: 27156124)
21. A fatal blood concentration of 5-APB.
Krpo M; Luytkis HC; Haneborg AM; Høiseth G
Forensic Sci Int; 2018 Oct; 291():e1-e3. PubMed ID: 30228015
[TBL] [Abstract][Full Text] [Related]
22. Alpha-methyltryptamine and 5-(2-methylaminopropyl)-benzofuran (5-MAPB) fatal co-intoxication: case report and review of literature.
Epain M; Cartiser N; Bevalot F; Bottinelli C; Chatenay C; Fanton L
Int J Legal Med; 2024 Apr; ():. PubMed ID: 38649548
[TBL] [Abstract][Full Text] [Related]
23. A combined toxicokinetic and metabolic approach to investigate deschloro-N-ethylketamine exposure in a multidrug user.
Magny R; Mégarbane B; Chevillard L; Roulland E; Bardèche-Trystram B; Dumestre-Toulet V; Labat L; Houzé P
J Pharm Biomed Anal; 2024 Jun; 243():116086. PubMed ID: 38518457
[TBL] [Abstract][Full Text] [Related]
24. Distinguishing of 2-MAPB and 6-MAPB: Solution of the problem.
Shevyrin V; Shafran Y
J Mass Spectrom; 2017 Oct; 52(10):633-637. PubMed ID: 28708288
[TBL] [Abstract][Full Text] [Related]
25. An Internet snapshot study to compare the international availability of the novel psychoactive substance methiopropamine.
Vermette-Marcotte AE; Dargan PI; Archer JR; Gosselin S; Wood DM
Clin Toxicol (Phila); 2014 Aug; 52(7):678-81. PubMed ID: 25089723
[TBL] [Abstract][Full Text] [Related]
26. Implications of psychoactive 'bath salts' use during pregnancy.
Gray BA; Holland C
Nurs Womens Health; 2014; 18(3):220-30. PubMed ID: 24939199
[TBL] [Abstract][Full Text] [Related]
27. New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems.
Welter-Luedeke J; Maurer HH
Ther Drug Monit; 2016 Feb; 38(1):4-11. PubMed ID: 26327309
[TBL] [Abstract][Full Text] [Related]
28. Postmortem distribution and redistribution of MDAI and 2-MAPB in blood and alternative matrices.
Staeheli SN; Boxler MI; Oestreich A; Marti M; Gascho D; Bolliger SA; Kraemer T; Steuer AE
Forensic Sci Int; 2017 Oct; 279():83-87. PubMed ID: 28850871
[TBL] [Abstract][Full Text] [Related]
29. Death following consumption of MDAI and 5-EAPB.
Deville M; Dubois N; Cieckiewicz E; De Tullio P; Lemaire E; Charlier C
Forensic Sci Int; 2019 Jun; 299():89-94. PubMed ID: 30981086
[TBL] [Abstract][Full Text] [Related]
30. Structural confirmation of position isomers 2-(2-methylaminoprolyl)benzofuran and 5-(2-methylaminopropyl)benzofuran: a combined mass spectrometric and computational study.
Xu Y; Lin X; Chen X; Ke X; Wu H; Fan YL; Zhou J; Xu J
Rapid Commun Mass Spectrom; 2024 Feb; 38(4):e9688. PubMed ID: 38212651
[TBL] [Abstract][Full Text] [Related]
31. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
[TBL] [Abstract][Full Text] [Related]
32. Cristalius: a case in designer drugs.
Lenz J; Brown J; Flagg S; Oh R; Batts K; Ditzler T; Johnson J
Mil Med; 2013 Jul; 178(7):e893-5. PubMed ID: 23820374
[TBL] [Abstract][Full Text] [Related]
33. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series.
Hill SL; Doris T; Gurung S; Katebe S; Lomas A; Dunn M; Blain P; Thomas SH
Clin Toxicol (Phila); 2013 Jul; 51(6):487-92. PubMed ID: 23731373
[TBL] [Abstract][Full Text] [Related]
34. Cross-reactivity of selected benzofurans with commercial amphetamine and ecstasy immunoassays in urine.
Gomila I; Moranta C; Quesada L; Pastor Y; Dastis M; Torrents A; Elorza MÁ; Busardò FP; Barceló B
Bioanalysis; 2017 Nov; 9(22):1771-1785. PubMed ID: 28975809
[TBL] [Abstract][Full Text] [Related]
35. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone.
Wood DM; Greene SL; Dargan PI
Emerg Med J; 2011 Apr; 28(4):280-2. PubMed ID: 20581379
[TBL] [Abstract][Full Text] [Related]
36. Ecstasy abuse in Ireland.
Cregg MT; Tracey JA
Ir Med J; 1993; 86(4):118-20. PubMed ID: 8103042
[TBL] [Abstract][Full Text] [Related]
37. Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases.
Gee P; Schep LJ; Jensen BP; Moore G; Barrington S
Clin Toxicol (Phila); 2016; 54(2):141-6. PubMed ID: 26621342
[TBL] [Abstract][Full Text] [Related]
38. Sudden cardiac death associated with methylone use.
Carbone PN; Carbone DL; Carstairs SD; Luzi SA
Am J Forensic Med Pathol; 2013 Mar; 34(1):26-8. PubMed ID: 23403480
[TBL] [Abstract][Full Text] [Related]
39. A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction.
Darracq MA; Thornton SL; Minns AB; Gerona RR
J Psychoactive Drugs; 2016; 48(5):351-354. PubMed ID: 27636207
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.
Wood DM; Sedefov R; Cunningham A; Dargan PI
Clin Toxicol (Phila); 2015 Feb; 53(2):85-92. PubMed ID: 25658166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
